TrialJCO precision oncology2025

Palbociclib, a Selective CDK4/6 Inhibitor, Administered Before and After Chemoradiotherapy for Human Papillomavirus-Negative, Locally Advanced Head and Neck Squamous Cell Carcinoma: A Single-Arm, Phase II Trial.

Peter J Oppelt et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.